APL • ISIN: INE0SJX01015
Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally.
The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more.
The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers.
The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing.
Products:
Albendazole USP 400 mg: Albendazole USP 400 mg refers to a higher dosage of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication that is used to treat various parasitic worm infections.
Diclofenac 100 mg: Diclofenac 100 mg refers to a specific dosage of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID).
Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two commonly used over-the-counter medications, often used to relieve pain and reduce fever.
Ferrovit Syrup: To treat vitamin and mineral deficiencies.
As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments.
Competitive Strengths:
Formulation Expertise
Experienced Promoters
Wide range of Products
Strategic Location
Skilled Workforce
Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit
Funding the incremental working capital requirements of the Company
Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company
General Corporate Purposes
Price Band
Min Investment
Lot Size
P/E Ratio
Issue Opens
9 Jul 2025
Issue Closes
11 Jul 2025
Allotment
14 Jul 2025
Listing
16 Jul 2025
Qualified Institutional Investors
36,449,000 / 1,060,000 shares
High Networth Individuals (Above ₹10 Lakhs)
91,262,000 / 215,000 shares
Non-Institutional Investors (Below ₹10 Lakhs)
22,564,000 / 107,000 shares
Retail Individual Investors
128,416,000 / 746,000 shares
Issue Type | BB |
Face Value | ₹10 |
Lead Managers | Sobhagya Capital Options Ltd |
Min Quantity | 2,000 |
Max Quantity | 4,065 |
Company Promoters | Dr. Ashish Narayan Sakalkar Saili Jayaram |
Website | |
Phone | +91 22 49731411 |
Address | Asston Pharmaceuticals Ltd. |